"{\"sent_tag\": {\"5\": [[\"Our\", \"O\"], [\"deep\", \"O\"], [\"scientific\", \"O\"], [\"expertise\", \"O\"], [\"and\", \"O\"], [\"demonstrated\", \"O\"], [\"clinical\", \"O\"], [\"development\", \"O\"], [\"capabilities\", \"O\"], [\"support\", \"O\"], [\"our\", \"O\"], [\"commitment\", \"O\"], [\"to\", \"O\"], [\"aggressively\", \"O\"], [\"develop\", \"O\"], [\"and\", \"O\"], [\"launch\", \"O\"], [\"transformational\", \"O\"], [\"therapies\", \"O\"], [\"for\", \"O\"], [\"patients\", \"O\"], [\"with\", \"O\"], [\"cardiovascular\", \"O\"], [\"and\", \"O\"], [\"metabolic\", \"O\"], [\"diseases.\", \"O\"]], \"2\": [[\"HM12525A\", \"O\"], [\"is\", \"O\"], [\"an\", \"O\"], [\"oxyntomodulin-based\", \"O\"], [\"therapy\", \"O\"], [\"(GLP-1glucagon\", \"O\"], [\"receptor\", \"O\"], [\"dual\", \"O\"], [\"agonist)\", \"O\"], [\"that\", \"O\"], [\"has\", \"O\"], [\"shown\", \"O\"], [\"evidence\", \"O\"], [\"of\", \"O\"], [\"improving\", \"O\"], [\"multiple\", \"O\"], [\"metabolic\", \"O\"], [\"parameters\", \"O\"], [\"that\", \"O\"], [\"lead\", \"O\"], [\"to\", \"O\"], [\"improved\", \"O\"], [\"blood\", \"O\"], [\"glucose,\", \"O\"], [\"body\", \"O\"], [\"weight,\", \"O\"], [\"and\", \"O\"], [\"insulin\", \"O\"], [\"sensitivity.\", \"O\"]], \"1\": [[\"The\", \"O\"], [\"agreement\", \"O\"], [\"is\", \"O\"], [\"subject\", \"O\"], [\"to\", \"O\"], [\"clearance\", \"O\"], [\"under\", \"O\"], [\"the\", \"O\"], [\"Hart-Scott-Rodino\", \"O\"], [\"Antitrust\", \"O\"], [\"Improvements\", \"O\"], [\"Act\", \"O\"], [\"and\", \"O\"], [\"other\", \"O\"], [\"customary\", \"O\"], [\"closing\", \"O\"], [\"conditions.\", \"O\"]], \"4\": [[\"We\", \"O\"], [\"are\", \"O\"], [\"very\", \"O\"], [\"excited\", \"O\"], [\"about\", \"O\"], [\"this\", \"O\"], [\"agreement\", \"O\"], [\"with\", \"O\"], [\"Hanmi\", \"ORGANIZATION\"], [\"and\", \"O\"], [\"the\", \"O\"], [\"potential\", \"O\"], [\"of\", \"O\"], [\"HM12525A\", \"O\"], [\"to\", \"O\"], [\"improve\", \"O\"], [\"therapeutic\", \"O\"], [\"options\", \"O\"], [\"for\", \"O\"], [\"people\", \"O\"], [\"living\", \"O\"], [\"with\", \"O\"], [\"metabolic\", \"O\"], [\"diseases,\", \"O\"], [\"said\", \"O\"], [\"James\", \"PERSON\"], [\"List,\", \"O\"], [\"M.D.,\", \"O\"], [\"Ph.D.,\", \"O\"], [\"Global\", \"O\"], [\"Therapeutic\", \"O\"], [\"Area\", \"O\"], [\"Head,\", \"O\"], [\"Cardiovascular\", \"O\"], [\"&\", \"O\"], [\"Metabolism,\", \"O\"], [\"Janssen.\", \"O\"]], \"3\": [[\"This\", \"O\"], [\"asset\", \"O\"], [\"has\", \"O\"], [\"the\", \"O\"], [\"potential,\", \"O\"], [\"as\", \"O\"], [\"a\", \"O\"], [\"once\", \"O\"], [\"weekly\", \"O\"], [\"therapy,\", \"O\"], [\"to\", \"O\"], [\"be\", \"O\"], [\"a\", \"O\"], [\"best-in-class\", \"O\"], [\"oxyntomodulin-based\", \"O\"], [\"therapy,\", \"O\"], [\"according\", \"O\"], [\"toJohnson\", \"O\"], [\"&\", \"O\"], [\"Johnson.\", \"O\"]], \"6\": [[\"We\", \"O\"], [\"look\", \"O\"], [\"forward\", \"O\"], [\"to\", \"O\"], [\"developing\", \"O\"], [\"this\", \"O\"], [\"potential\", \"O\"], [\"best-in-class\", \"O\"], [\"therapy,\", \"O\"], [\"which\", \"O\"], [\"allows\", \"O\"], [\"us\", \"O\"], [\"to\", \"O\"], [\"build\", \"O\"], [\"on\", \"O\"], [\"our\", \"O\"], [\"success\", \"O\"], [\"in\", \"O\"], [\"diabetes\", \"O\"], [\"and\", \"O\"], [\"strengthen\", \"O\"], [\"our\", \"O\"], [\"metabolism\", \"O\"], [\"portfolio.\", \"O\"]], \"0\": [[\"IBM\", \"ORGANIZATION\"], [\"and\", \"O\"], [\"OpenPOWER\", \"O\"], [\"Members\", \"O\"], [\"Deliver\", \"O\"], [\"Accelerated\", \"O\"], [\"Technologies\", \"O\"], [\"to\", \"O\"], [\"Break\", \"O\"], [\"Big\", \"O\"], [\"Data\", \"O\"], [\"Speed\", \"O\"], [\"Barriers\", \"O\"], [\"The\", \"O\"], [\"FINANCIAL\", \"O\"], [\"--\", \"O\"], [\"Janssen\", \"ORGANIZATION\"], [\"Pharmaceuticals,\", \"ORGANIZATION\"], [\"Inc.\", \"ORGANIZATION\"], [\"(Janssen)\", \"O\"], [\"announced\", \"O\"], [\"on\", \"O\"], [\"November\", \"O\"], [\"9\", \"O\"], [\"that\", \"O\"], [\"it\", \"O\"], [\"has\", \"O\"], [\"obtained\", \"O\"], [\"worldwide\", \"O\"], [\"rights,\", \"O\"], [\"excluding\", \"O\"], [\"China\", \"LOCATION\"], [\"and\", \"O\"], [\"Korea,\", \"O\"], [\"to\", \"O\"], [\"develop\", \"O\"], [\"and\", \"O\"], [\"commercialize\", \"O\"], [\"oxyntomodulin-based\", \"O\"], [\"therapies\", \"O\"], [\"including\", \"O\"], [\"HM12525A,\", \"O\"], [\"a\", \"O\"], [\"biologic\", \"O\"], [\"that\", \"O\"], [\"is\", \"O\"], [\"completing\", \"O\"], [\"phase\", \"O\"], [\"1\", \"O\"], [\"and\", \"O\"], [\"expected\", \"O\"], [\"to\", \"O\"], [\"enter\", \"O\"], [\"phase\", \"O\"], [\"2\", \"O\"], [\"studies\", \"O\"], [\"next\", \"O\"], [\"year,\", \"O\"], [\"from\", \"O\"], [\"Hanmi\", \"ORGANIZATION\"], [\"Pharmaceutical\", \"ORGANIZATION\"], [\"Co.,\", \"ORGANIZATION\"], [\"Ltd.\", \"ORGANIZATION\"]]}, \"name\": \"IBM and OpenPOWER Members Deliver Accelerated Technologies to Break Big Data Speed Barriers\"}"